A Research Guide for
Facing Acute Myeloid Leukemia

• Full molecular and cytogenetic results begin returning, and your ELN 2022 risk group is assigned.
• The fit-versus-unfit decision is made: intensive 7+3 induction, or a venetoclax-based lower-intensity regimen.
• HLA typing (a blood or cheek-swab test) and a donor search should be started now for intermediate- and adverse-risk patients — not after remission, because finding a donor takes weeks.

Ask: “Am I fit for intensive induction, or is a venetoclax-based regimen safer for me — and what specifically makes you say so?”

Ask: “Does my leukemia have a mutation with a matched drug — a FLT3, IDH, or menin inhibitor — and will it be part of my first treatment?”

• Induction chemotherapy is underway, or your first venetoclax cycle has begun with the slow ramp-up that prevents tumor lysis syndrome.
• A bone marrow biopsy around day 14 checks whether the leukemia is clearing.
• Learn the warning signs of differentiation syndrome (fever, breathlessness, swelling) if you are on an IDH or menin inhibitor, and the neutropenic-fever rule: any temperature of 100.4°F / 38°C is a medical emergency — go to the emergency department.

Ask: “What are the stop rules for each of my drugs — when would you hold or stop this treatment, and which symptoms should make me call you immediately?”

• Once your blood counts recover, a bone marrow biopsy confirms whether you are in complete remission.
• MRD (measurable residual disease) testing begins, and its results guide what comes next.

• Based on your risk group and MRD, you proceed to consolidation chemotherapy or an allogeneic stem cell transplant.
• If a transplant is planned, your donor should already be identified from the search started in week 1.
• Longer term: continued MRD surveillance and, for some patients, maintenance therapy (such as oral azacitidine) or post-transplant follow-up.

Ask: “Given my ELN risk and MRD result, do I need a transplant in first remission, and is my donor search already underway?”

FDA-APPROVED Revumenib is the first-in-class menin inhibitor. It was initially approved in November 2024 for adults and children with relapsed or refractory AML harboring KMT2A rearrangements. In October 2025, the FDA expanded the indication to include NPM1-mutated R/R AML. These genetic changes are found in roughly 30–40% of AML patients combined. In the AUGMENT-101 trial, revumenib achieved complete remission or complete remission with partial hematologic recovery (CR/CRh) in approximately 21% of heavily pretreated patients — a meaningful response in a population with very limited options. Requires QTc monitoring.

FDA-APPROVED The VIALE-A trial established venetoclax + azacitidine as the new standard of care for older or unfit AML patients. This combination roughly doubled response rates and improved median overall survival compared to azacitidine alone (14.7 months vs. 9.6 months). For patients with IDH1/2 or NPM1 mutations, outcomes were even better, with some achieving durable remissions lasting years.

FDA-APPROVED CPX-351 is a liposomal formulation of daunorubicin and cytarabine in a fixed 5:1 ratio. In a randomized trial, it improved overall survival compared to standard 7+3 in patients aged 60–75 with therapy-related AML or AML with myelodysplasia-related changes. More patients who received CPX-351 were able to proceed to stem cell transplant.

FDA-APPROVED The QUAZAR AML-001 trial showed that oral azacitidine maintenance therapy, given after achieving first complete remission in patients aged 55 or older who were not candidates for transplant, improved overall survival by approximately 10 months compared to placebo. This was the first maintenance therapy to show a survival benefit in AML.

FDA-APPROVED FLT3 mutations are found in roughly 25–30% of AML patients. Three FLT3 inhibitors are now FDA-approved:

• Midostaurin (Rydapt): Added to 7+3 induction in newly diagnosed FLT3-mutated AML (RATIFY trial). Improved overall survival.
• Gilteritinib (Xospata): Single-agent for relapsed/refractory FLT3-mutated AML (ADMIRAL trial). Doubled response rates vs. salvage chemotherapy.
• Quizartinib (Vanflyta): Added to 7+3 induction for newly diagnosed FLT3-ITD AML (QuANTUM-First trial). PMDA (Japan) approved June 2019 for relapsed/refractory FLT3-ITD AML (QuANTUM-R trial), expanded May 2023 to newly diagnosed. FDA approved 2023 for newly diagnosed FLT3-ITD AML. Note: Quizartinib is specific to FLT3-ITD mutations only, unlike midostaurin which covers both ITD and TKD.

FDA-APPROVED Ivosidenib combined with azacitidine for newly diagnosed IDH1-mutated AML doubled the response rate and improved overall survival compared to azacitidine alone in the AGILE trial. IDH1 mutations are found in approximately 6–10% of AML patients. Additional IDH inhibitors include enasidenib (IDH2) and olutasidenib (IDH1).

AML is often first suspected from a complete blood count (CBC) showing abnormal numbers of white blood cells (very high or very low), low red blood cells (anemia), and low platelets (thrombocytopenia). A peripheral blood smear examined under a microscope may show blast cells — immature cells that are not normally found in the bloodstream.

A bone marrow biopsy is required to confirm AML. A needle is inserted into the hip bone to withdraw a sample of marrow. The sample is examined for blast percentage (20% or more blasts confirms AML in most cases), cell appearance (morphology), and is sent for flow cytometry, cytogenetics, and molecular testing. This procedure takes about 15–30 minutes and is done under local anesthesia, sometimes with sedation.

Flow cytometry uses laser technology to identify the surface proteins on leukemia cells. This confirms whether the blasts are myeloid (AML) or lymphoid (ALL), identifies the specific AML subtype, and establishes a baseline “fingerprint” that can be tracked later to detect minimal residual disease (MRD).

Conventional karyotyping examines the chromosomes of leukemia cells for abnormalities. Results take 7–14 days. Key findings include:

• t(15;17): Diagnostic of APL — requires emergent ATRA treatment
• t(8;21) or inv(16): Core-binding factor AML — favorable risk
• Complex karyotype (3 or more abnormalities): Adverse risk
• Normal karyotype: Risk depends on molecular mutations
• Monosomal karyotype: Adverse risk

FISH (fluorescence in situ hybridization) can provide faster results for specific abnormalities and is often used to rapidly confirm or rule out APL.

A generation ago, almost everyone with AML received essentially the same chemotherapy, and the main thing that distinguished one person's treatment from another's was their age and general fitness. That has changed completely. AML is now understood not as a single disease but as a family of related diseases, each defined by the specific genetic changes driving it — and the genetic profile of your leukemia, more than almost anything else, determines which treatments are likely to work for you. This is why your team places such emphasis on molecular testing at diagnosis, and why it is worth waiting (when it is safe to wait) for those results before finalizing a plan.

There are two distinct kinds of information these tests provide, and it helps to keep them separate in your mind. The first is prognosis: certain mutations (such as NPM1 without FLT3-ITD, or the core-binding-factor changes) tend to predict a better response to treatment, while others (such as TP53, or a complex set of chromosome changes) predict a more difficult course. This information feeds into your risk group and into decisions such as whether you need a transplant. The second kind of information is actionability: some mutations have a specific drug designed to attack them. A FLT3 mutation can be matched to a FLT3 inhibitor, an IDH1 or IDH2 mutation to an IDH inhibitor, and an NPM1 or KMT2A change to a menin inhibitor. In these cases, the test result does not just predict your future — it directly opens a treatment door.

This is also why the timing of testing matters so much. Rapid testing for FLT3 (and for the PML::RARA change that defines the emergency subtype APL) is prioritized because the results change what is given in the very first days of treatment. Broader panels, which take a little longer, refine the risk assessment and may reveal additional targets. A reasonable expectation is that your team will run a comprehensive panel — not just one or two genes — because an incomplete picture can lead to underestimating the leukemia and under-treating it. If you are ever unsure what was tested, it is entirely appropriate to ask for the list.

FLT3 is a growth signal that, when mutated, drives leukemia cells to multiply rapidly. There are two types:

• FLT3-ITD (internal tandem duplication): The more common and more concerning type. ELN 2022 removed allelic ratio from risk classification — any FLT3-ITD is now considered regardless of ratio. Treated with FLT3 inhibitors added to chemotherapy.
• FLT3-TKD (tyrosine kinase domain): A point mutation. Less clearly prognostic but still targeted by some FLT3 inhibitors.

Why it matters: If you have a FLT3 mutation, a FLT3 inhibitor should be added to your induction chemotherapy from day 1. Midostaurin covers both FLT3-ITD and FLT3-TKD mutations; quizartinib is approved only for FLT3-ITD. This is why rapid FLT3 testing is essential — it must be back before treatment starts.

NPM1 is the most commonly mutated gene in AML. When present without FLT3-ITD, it indicates favorable risk per ELN 2022. NPM1-mutated with FLT3-ITD (regardless of allelic ratio) is classified as intermediate risk. NPM1-mutated AML responds well to intensive chemotherapy and venetoclax-based regimens. NPM1 mutations also make patients eligible for the menin inhibitors revumenib and ziftomenib if they relapse. NPM1 is an excellent marker for MRD monitoring.

Biallelic CEBPA mutations (or single in-frame bZIP mutations per ELN 2022) define favorable-risk AML. These patients have excellent outcomes with intensive chemotherapy alone, and many do not need transplant in first remission. Germline CEBPA mutations (inherited) can cause familial AML — genetic counseling may be recommended.

IDH mutations cause leukemia cells to produce an abnormal metabolite (2-hydroxyglutarate) that blocks normal cell maturation. Targeted IDH inhibitors can force these stuck cells to mature into normal blood cells — a process called differentiation.

• IDH1 mutations: Targeted by ivosidenib (Tibsovo) and olutasidenib (Rezlidhia)
• IDH2 mutations: Targeted by enasidenib (Idhifa)

Important safety note: IDH inhibitors can cause differentiation syndrome — fever, fluid retention, breathing difficulty, and sometimes organ damage as leukemia cells rapidly mature. This is treatable with steroids if caught early, but patients and families should know the warning signs.

TP53 is a tumor suppressor gene. When mutated, leukemia cells become resistant to many standard treatments. TP53-mutated AML is classified as adverse risk by ELN 2022 and remains the most challenging subgroup in AML.*

*ELN 2022 specifies that TP53 mutations must have a variant allele frequency (VAF) ≥10% to be classified as adverse risk. Mutations below this threshold may represent subclonal events with uncertain significance. Confirm VAF with your hematologist.

Honest assessment: Median overall survival with current treatments is approximately 5–9 months. Response to venetoclax-based regimens is lower and less durable. Even transplant has high relapse rates in TP53-mutated AML. Clinical trials exploring novel approaches (including CD47 antibodies, immune checkpoint combinations, and decitabine/cedazuridine) are strongly recommended for this group.

KMT2A (formerly called MLL) rearrangements create fusion genes that hijack normal gene regulation. Common in infant leukemia and therapy-related AML. Classified as adverse or intermediate risk depending on the specific fusion partner. KMT2A-rearranged AML is now targetable by the menin inhibitor revumenib (Revuforj), which was FDA-approved in November 2024 for relapsed/refractory KMT2A-rearranged AML (expanded in October 2025 to include NPM1-mutated R/R AML). A second menin inhibitor, ziftomenib (Komzifti), was approved in November 2025 for NPM1-mutated R/R AML.

Being placed in a risk group can feel like being handed a verdict, so it is worth understanding what the categories actually represent. A risk group is a statement about averages: it describes how groups of patients with similar genetic features have tended to respond to treatment in large studies. It is genuinely useful, because those averages guide concrete decisions — most importantly, whether the benefit of a stem cell transplant in first remission outweighs its risks. Favorable-risk disease is often controlled with chemotherapy alone; adverse-risk disease usually calls for transplant. That is the practical purpose the categories serve.

What a risk group cannot do is predict your individual outcome. Plenty of people with adverse-risk features achieve remission and long-term survival, particularly now that targeted drugs and modern transplant techniques have improved the odds; and some people with favorable-risk features relapse. Your category is a starting point for planning, not a prophecy. It is also not fixed: your response to the first round of treatment, and especially your measurable residual disease result, can move you in effect into a different risk picture and change the recommendation. A favorable-risk leukemia that does not clear on sensitive testing is treated more cautiously; an intermediate-risk leukemia that clears deeply may need less aggressive treatment.

Finally, risk grouping is one of several inputs into your care, not the whole story. Your age, fitness, other health conditions, personal priorities, and the specific drugs your leukemia can be matched to all shape the plan alongside the risk category. The most useful way to use your risk group is as a framework for asking good questions — “given my risk and my MRD results, what does a transplant add for me, and what are its risks?” — rather than as a number that decides your future on its own.

• What are my specific genetic mutations and cytogenetics?
• What is my ELN 2022 risk category?
• Has APL (PML::RARA) been ruled out?
• Are there any mutations that have a specific targeted therapy available?
• Should I start a donor search for transplant now, even before we know the full results?
• Is there a clinical trial available for my specific mutation profile?
• How will MRD testing be used to guide my treatment?
• Do I have therapy-related or secondary AML, and does that change my treatment?

“7+3” refers to 7 days of continuous cytarabine infusion plus 3 days of an anthracycline (daunorubicin or idarubicin). This has been the foundation of AML treatment for decades. It achieves complete remission in approximately 60–80% of younger patients.

What to expect: Chemotherapy is given through a central line (usually a PICC line or Hickman catheter). The bone marrow is intentionally depleted of both leukemia cells and normal cells, causing a period of very low blood counts (aplasia) lasting 2–4 weeks. During this time, patients require blood and platelet transfusions and are at high risk of infection. A bone marrow biopsy is performed around day 14 to assess response, and again at count recovery.

Targeted add-ons: For FLT3-mutated AML, midostaurin (days 8–21) is added to 7+3 (covers both ITD and TKD). For FLT3-ITD specifically, quizartinib is an alternative. For CD33-positive favorable-risk AML, gemtuzumab ozogamicin (Mylotarg) may be added.

FDA-APPROVED CPX-351 is preferred over standard 7+3 for patients aged 60–75 with therapy-related AML or AML arising from MDS. It delivers the same two drugs (cytarabine and daunorubicin) in a liposomal formulation that maintains the optimal 5:1 drug ratio inside cells. The pivotal trial showed improved overall survival and higher rates of proceeding to transplant compared to standard 7+3.

Achieving remission is not enough. Without consolidation therapy, most patients will relapse. Consolidation options depend on risk group:

• Favorable risk: 2–4 cycles of high-dose cytarabine (HiDAC). Each cycle requires approximately 1 week of hospitalization with subsequent count recovery.
• Intermediate risk: 1–2 cycles of HiDAC followed by allogeneic stem cell transplant (discussed in the Transplant section).
• Adverse risk: Proceed to allogeneic stem cell transplant as soon as a donor is identified and the patient is in remission.

Lower-intensity treatment is often misunderstood as “giving up” or settling for less, when in fact, for the right patient, it represents a deliberate and increasingly effective strategy. The arrival of venetoclax-based combinations has changed what these regimens can achieve: response rates that were once the preserve of intensive hospital-based chemotherapy are now attainable with treatment that is largely given in the clinic and at home. For many older adults, this means meaningful disease control without the prolonged hospitalization and marrow aplasia that intensive induction requires.

Practically, the rhythm of life on a venetoclax-based regimen is different from intensive treatment. Therapy is organized in 28-day cycles, with the hypomethylating agent given over the first several days (by injection, or now as a take-home tablet with the all-oral option) and venetoclax taken daily by mouth. The first cycle usually involves the closest monitoring — including the venetoclax ramp-up to prevent tumor lysis syndrome, sometimes with a short hospital stay — after which most care shifts to regular clinic visits for blood counts and supportive care. Low blood counts remain the main challenge, so transfusions and infection precautions are still part of life, but the overall burden is generally lighter than with intensive therapy.

It is also worth understanding that lower-intensity treatment is typically continuous rather than a fixed course: it is given for as long as it is working and tolerated, rather than stopping after a set number of cycles. This continuity is part of why it works, and it is a reason to plan for the long term — arranging reliable transport to appointments, managing other medications carefully because of interactions (especially antifungal drugs with venetoclax), and keeping the lines of communication with your team open about side effects. A regimen that is adjusted thoughtfully and continued is far more effective than one that is stopped at the first sign of low counts.

FDA-APPROVED The VIALE-A trial established venetoclax + azacitidine as the standard of care for newly diagnosed AML patients aged 75 or older, or those with comorbidities precluding intensive chemotherapy. Key results:

• Complete remission rate (CR+CRi): approximately 66% vs. 28% with azacitidine alone
• Median overall survival: 14.7 months vs. 9.6 months
• Patients with IDH1/2 mutations had particularly strong responses (median OS not reached in some analyses)
• Patients with NPM1 mutations also showed excellent outcomes
• TP53-mutated patients had lower response rates and shorter duration of response

How it works: Venetoclax blocks BCL-2, a protein that prevents leukemia cells from dying, and it acts synergistically with azacitidine — the combination benefit is far greater than either drug alone. Azacitidine is a hypomethylating agent given as a subcutaneous injection for 7 days per 28-day cycle. Venetoclax is taken orally daily with a ramp-up schedule in the first cycle to prevent tumor lysis syndrome. Treatment continues until progression or intolerance.

FDA-APPROVED An alternative for patients who cannot receive azacitidine. The VIALE-C trial showed improved CR rates with venetoclax + LDAC compared to LDAC alone. Generally considered slightly less effective than ven/aza, but remains an option when hypomethylating agents are not suitable.

FDA-APPROVED On May 13, 2026, the FDA approved oral decitabine and cedazuridine tablets (Inqovi) combined with venetoclax for newly diagnosed AML in adults 75 or older, or who have other health conditions that make intensive chemotherapy unsafe — the same group treated with venetoclax + azacitidine. This is the first all-oral frontline regimen for these patients: the hypomethylating agent becomes a take-home tablet instead of several days of subcutaneous azacitidine injections each cycle.

How it works: Cedazuridine blocks the enzyme that would otherwise break decitabine down in the gut, so the hypomethylating agent can be absorbed as a pill. The recommended dose is one tablet (35 mg decitabine / 100 mg cedazuridine) once daily on Days 1–5 of each 28-day cycle, taken together with venetoclax. Approval was based on Study ASTX727-07 (NCT04657081), a single-arm trial in 101 patients. Inqovi was first approved in 2020 for myelodysplastic syndromes and CMML.

Ask: "Is the all-oral regimen an option for me instead of injectable azacitidine, and would taking the hypomethylating agent at home change my monitoring schedule or my tumor lysis risk during the venetoclax ramp-up?"

Before venetoclax combinations became available, hypomethylating agents (HMAs) alone were the standard lower-intensity option. HMA monotherapy achieves lower response rates (CR approximately 15–25%) and shorter duration of response compared to venetoclax combinations. It may still be considered for patients who cannot tolerate venetoclax (e.g., due to drug interactions or severe cytopenias), but venetoclax combinations are now strongly preferred when feasible.

It helps to understand why targeted therapies behave so differently from traditional chemotherapy, because that difference shapes what you can expect from them. Standard chemotherapy works by poisoning rapidly dividing cells. It is powerful and often curative, but it cannot tell the difference between leukemia cells and the body's other fast-growing cells — which is why it causes low blood counts, hair loss, and mouth sores. Targeted drugs take a different approach: each is designed to interfere with a specific molecular fault inside the leukemia cell. Because they aim at something the cancer depends on more than healthy cells do, their side effects tend to be different — and sometimes milder — than those of chemotherapy, though they are by no means free of risk.

A particularly important feature of several AML targeted drugs — the IDH inhibitors and the menin inhibitors — is that they do not simply kill the leukemia cell; they coax it to grow up. AML is, at its root, a disease in which immature blood cells are frozen at an early stage and multiply instead of maturing. These drugs release that block, allowing the leukemia cells to mature into more normal blood cells. This “differentiation” mechanism explains two things you may notice: responses can take longer to appear (sometimes months rather than weeks), and there is a specific side effect — differentiation syndrome — in which the wave of maturing cells causes fever, fluid buildup, and breathing difficulty. Caught early, it is very treatable with steroids, which is why your team will warn you about its warning signs.

Two practical points follow. First, because targeted therapy depends entirely on having the right target, the choice of drug is dictated by your molecular test results — there is no benefit to a FLT3 inhibitor without a FLT3 mutation. Second, leukemia can become resistant to a targeted drug over time, often by finding a way around the blocked pathway, which is why these drugs are frequently combined with chemotherapy or used as a bridge to transplant rather than relied on alone. Used in the right patient at the right time, they have genuinely changed what is possible in AML.

FDA-APPROVED For patients with FLT3 mutations (~25–30% of AML)

Important drug interactions: FLT3 inhibitors interact with many other medications through the CYP3A4 liver enzyme pathway. Strong CYP3A4 inhibitors (e.g., certain antifungals like posaconazole, voriconazole) require dose adjustments. Always inform your pharmacist of all medications.

FDA-APPROVED For patients with IDH1 mutations (~6–10% of AML)

• Ivosidenib (Tibsovo): FDA-approved as monotherapy for relapsed/refractory IDH1-mutated AML and in combination with azacitidine for newly diagnosed IDH1-mutated AML in patients not eligible for intensive chemotherapy. The AGILE trial (NCT03173248) showed ivosidenib + azacitidine improved median OS to 24.0 months vs. 7.9 months with placebo + azacitidine.
• Olutasidenib (Rezlidhia): FDA-approved for relapsed/refractory IDH1-mutated AML. May be an option when ivosidenib is not tolerated or available.

FDA-APPROVED For patients with IDH2 mutations (~8–12% of AML)

Enasidenib (Idhifa) is FDA-approved for relapsed/refractory IDH2-mutated AML. It achieved an overall response rate of approximately 40% in the phase 1/2 AG-221-C-001 trial, with some patients achieving durable complete remissions. Like IDH1 inhibitors, enasidenib can cause differentiation syndrome. Bilirubin elevation is common and expected (a pharmacologic effect, not liver damage), but should be monitored.

FDA-APPROVED For patients with KMT2A rearrangements or NPM1 mutations (~30–40% of AML combined)

Revumenib (Revuforj) is the first menin inhibitor approved by the FDA — initially in November 2024 for relapsed/refractory AML with KMT2A rearrangements, then expanded in October 2025 to include NPM1-mutated R/R AML. The AUGMENT-101 trial (NCT04065399) showed a CR/CRh rate of approximately 21% in heavily pretreated patients. While this number may seem modest, these patients had very few other options.

Key considerations:

• Requires QTc monitoring (can prolong QT interval)
• CYP3A4 interactions require dose adjustments with azole antifungals
• Can cause differentiation syndrome (similar to IDH inhibitors)
• Ziftomenib (Komzifti), a second menin inhibitor, was FDA-approved November 13, 2025 for relapsed/refractory AML with NPM1 mutations based on the KOMET-001 trial (NCT04067336)

FDA-APPROVED Gemtuzumab ozogamicin is an antibody-drug conjugate targeting CD33, a protein found on most AML cells. It was originally approved in 2000, voluntarily withdrawn in 2010 after a confirmatory trial failed (at a dose that was too high), then re-approved in 2017 at a lower, fractionated dose based on the ALFA-0701 trial.

It is primarily recommended for favorable-risk, CD33-positive AML added to standard induction. The benefit is clearest in core-binding factor AML (t(8;21) or inv(16)). It is not recommended for adverse-risk AML.

Risk: Can cause hepatic veno-occlusive disease (VOD/SOS), particularly if given close to stem cell transplant. Careful timing is required.

Doses reflect standard FDA prescribing information and widely used regimens; consolidation and dose reductions are individualized. Verify every number with your treating team and the current label.

Every AML drug has situations in which your team will pause or stop it. Understanding these stop rules in advance helps you recognize when to call. Ask your doctor: "What are the specific numbers — temperature, lab values, or ECG readings — that would make you hold or stop each of my drugs?"

• Venetoclax — tumor lysis syndrome (TLS): The dose is raised on a fixed ramp (100 mg, then 200 mg, then 400 mg over three days), and blood chemistries are checked roughly 6–8 hours and 24 hours after each increase. The stop rule: if TLS labs shift dangerously — a rising potassium, phosphate, or uric acid, or a falling calcium — the next dose is held and the abnormality is corrected before continuing. When a strong CYP3A4 antifungal such as posaconazole is added, the venetoclax dose is cut sharply (often by at least 75%); discontinue if severe cytopenias or intolerance persist.
• Anthracycline (daunorubicin/idarubicin) — lifetime heart limit: Anthracyclines have a cumulative ceiling (roughly 550 mg/m2 for daunorubicin) to protect the heart. Your team tracks the running total and will stop the anthracycline once that limit is reached, even if more chemotherapy is otherwise planned. Echocardiograms monitor heart function; stop if the ejection fraction drops significantly.
• FLT3 and menin inhibitors (quizartinib, gilteritinib, revumenib) — QT interval: These can lengthen the heart’s QT interval. A common stop rule: hold the drug if the QTc exceeds 500 ms on ECG, correct potassium and magnesium, and discontinue if a dangerous arrhythmia occurs. Quizartinib is dispensed only through a REMS program because of this risk.
• IDH and menin inhibitors — differentiation syndrome: At the first suspicion (fever, breathlessness, swelling, low blood pressure), dexamethasone about 10 mg every 12 hours is started and the drug is interrupted if symptoms are severe; it is usually restarted once the reaction resolves. This is a when-to-stop-temporarily rule, not a reason to abandon an effective drug permanently.
• Gemtuzumab ozogamicin — transplant timing: It should not be given within 2 months of a stem cell transplant because of the risk of liver veno-occlusive disease; that timing is itself a stop rule.
• Neutropenic fever — a when-to-act rule: Any temperature of 38.0°C / 100.4°F during low counts triggers IV antibiotics within an hour. This is not a reason to stop chemotherapy, but it is a hard rule for immediate action — go to the emergency department.

FDA-APPROVED Oral azacitidine (Onureg) is the first maintenance therapy to show an overall survival benefit in AML. The QUAZAR AML-001 trial (NCT01757535) enrolled patients aged 55 or older in first CR/CRi who were not candidates for transplant. Key results:

• Median OS: 24.7 months vs. 14.8 months with placebo
• Median relapse-free survival: 10.2 months vs. 4.8 months
• Taken orally for 14 days per 28-day cycle
• Most common side effects: nausea, vomiting, low blood counts

Note: Oral azacitidine (Onureg) is a different formulation from injectable azacitidine (Vidaza). They are not interchangeable.

Ask: "Am I a candidate for oral azacitidine maintenance, and what survival benefit did the QUAZAR AML-001 trial show for someone like me?"

GUIDELINE-SUPPORTED For patients with FLT3-ITD AML who undergo allogeneic transplant, sorafenib maintenance starting after engraftment has been shown to significantly reduce relapse risk. The SORMAIN trial showed improved 2-year relapse-free survival of 85% with sorafenib vs. 53% with placebo. Sorafenib is a multi-kinase inhibitor with FLT3 activity. Common side effects include hand-foot skin reaction and diarrhea.

For most of the history of leukemia treatment, “remission” meant that a pathologist looking through a microscope could no longer find leukemia cells in the bone marrow. We now know that this kind of remission can still leave behind hundreds of thousands of leukemia cells — far too few to see, but more than enough to regrow the disease over the following months. Measurable residual disease testing closes that gap. By using molecular and immune-based methods that are hundreds to thousands of times more sensitive than the microscope, it answers a question that used to be unanswerable: not just “is there visible leukemia?” but “how completely has the treatment actually cleared the disease?”

This matters because the depth of remission, not just its presence, increasingly drives the most important decisions in your care. Two patients can both be “in remission” by the old definition and yet face very different futures: one whose MRD test is negative has a substantially lower chance of relapse, while one whose MRD remains positive may benefit from a change in strategy — such as moving to transplant — even if everything else about their leukemia looked favorable. In effect, MRD lets your team tailor the intensity of treatment to the individual leukemia rather than treating everyone in the same risk group identically.

Perhaps the most powerful use of MRD is as an early-warning system. In leukemias that can be tracked by a sensitive molecular marker (such as an NPM1 mutation), a rising level can signal that relapse is coming months before it would show up on a routine blood count or marrow biopsy. That early signal creates a window to act — to intervene while the amount of disease is still small and more controllable — rather than waiting for a full relapse to declare itself. This is why your team may continue checking MRD at intervals even after you feel completely well.

• Multiparameter flow cytometry (MFC): Detects leukemia cells by their unique surface protein pattern. Sensitivity approximately 1 in 10,000 cells (10^-4). Widely available.
• Quantitative PCR (qPCR): Detects specific molecular targets like NPM1 mutations or fusion genes (e.g., RUNX1::RUNX1T1 in t(8;21) AML). Sensitivity approximately 1 in 100,000 to 1 in 1,000,000 cells (10^-5 to 10^-6). The most sensitive method for trackable mutations.
• Next-generation sequencing (NGS): Can track multiple mutations simultaneously. Sensitivity varies (10^-3 to 10^-4). Increasingly used but not yet standardized for all mutations.

• MRD-negative: No detectable leukemia by the sensitivity of the test used. This is a strong favorable sign. Patients who achieve MRD negativity have significantly better outcomes.
• MRD-positive: Leukemia is still detectable at very low levels. This does not necessarily mean treatment has failed, but it may prompt a change in strategy — such as proceeding to transplant, changing treatment, or increasing monitoring frequency.

How MRD guides decisions:

• Favorable-risk patients who are MRD-negative after consolidation may be safely monitored without transplant.
• Favorable-risk patients who remain MRD-positive may benefit from transplant even though their genetic risk is otherwise good.
• Intermediate-risk patients use MRD to help decide transplant timing.
• Rising MRD levels after treatment may detect relapse months before it would be visible on blood counts or bone marrow, allowing earlier intervention.

One of the hardest things to prepare for with AML is the length and nature of the hospital stay. Initial (induction) chemotherapy usually means four to six weeks in the hospital — not because the chemotherapy itself takes that long, but because of what happens afterward. The treatment deliberately wipes out the bone marrow to clear the leukemia, and it then takes several weeks for healthy blood cells to regrow. During that recovery period your white blood cell count, which fights infection, falls to nearly zero, so you remain in the hospital where infections can be caught and treated immediately.

Day to day, this means frequent blood tests (often daily), transfusions of red cells and platelets as needed, and close monitoring for fever. A fever during this period is treated as an emergency, with antibiotics started within an hour, because without white cells your body cannot fight infection on its own. Much of the time you may actually feel reasonably well between waves of side effects — the difficulty is more often the boredom, isolation, and uncertainty of a long confinement than constant physical illness. Many people find it helps to plan for this: bringing familiar items from home, setting a daily routine, staying gently active when able, and arranging visits or video calls.

It also helps to know the general shape of the journey in advance. After induction comes a bone marrow biopsy to check whether you are in remission; if so, consolidation treatment follows, which may be additional cycles of chemotherapy (sometimes with shorter hospital stays) or a stem cell transplant. Understanding that the first hospitalization is the beginning of a planned sequence — not an open-ended ordeal — can make the experience more bearable.

During AML treatment you will hear your blood counts discussed constantly, and understanding what the numbers mean can make the experience feel less bewildering and more like something you are participating in. Three counts matter most. The white blood cells, and in particular the neutrophils, are your defense against infection; when the neutrophil count falls very low (a state called neutropenia), you are vulnerable to serious infection, which is why so much of your care during this period focuses on preventing and rapidly treating fevers. The hemoglobin reflects your red blood cells, which carry oxygen; when it falls, you feel tired and short of breath, and a transfusion can relieve those symptoms. The platelets help your blood clot; when they fall too low, you bruise and bleed easily, and platelet transfusions reduce that risk.

What can be confusing — and important to understand — is that low counts during treatment are usually a sign that the treatment is doing its job, not a sign that something has gone wrong. The chemotherapy clears the leukemia by emptying the bone marrow, and the healthy cells fall along with the leukemic ones before regrowing. Watching the counts begin to recover is one of the milestones your team looks for after each cycle, because it signals that the healthy marrow is coming back.

You will also hear about the “nadir,” the point at which the counts reach their lowest level (often a week or two after chemotherapy), and about “count recovery,” when they climb back toward normal. Knowing roughly where you are in that cycle helps explain how you feel and what precautions matter most on a given day — strict infection precautions during the nadir, for example, easing as the neutrophils return.

Most AML patients require multiple transfusions during treatment:

• Red blood cell transfusions: Given when hemoglobin drops below approximately 7–8 g/dL, or when causing significant symptoms (fatigue, shortness of breath, rapid heart rate).
• Platelet transfusions: Given when platelet count drops below approximately 10,000/µL, or below 50,000 if there is active bleeding or a procedure is needed.
• Transfusions are routine and safe in the hospital setting. Irradiated and leukoreduced blood products are standard for AML patients.

Infection is the leading cause of death during AML treatment. During periods of severe neutropenia (very low white blood cells, typically <500 neutrophils/µL), the body has almost no ability to fight bacteria and fungi.

• Antibacterial prophylaxis: Fluoroquinolone antibiotics (levofloxacin or ciprofloxacin) are commonly given during neutropenia.
• Antifungal prophylaxis: Posaconazole or voriconazole are standard during induction. Fungal infections (Aspergillus, Candida) are a major risk in prolonged neutropenia. Note: Many antifungals interact with targeted therapies (FLT3 inhibitors, venetoclax, menin inhibitors) — dose adjustments are critical.
• Antiviral prophylaxis: Acyclovir or valacyclovir to prevent herpes simplex and varicella-zoster reactivation.
• Neutropenic fever protocol: Any fever (38.0°C / 100.4°F or higher) during neutropenia is treated as a medical emergency. Broad-spectrum IV antibiotics are started immediately, before culture results are available.

• G-CSF (filgrastim, pegfilgrastim): White blood cell growth factors may be used after consolidation to shorten the duration of neutropenia. Their use during induction is more controversial and varies by center.
• Tumor lysis syndrome (TLS) prevention: Patients with very high white blood cell counts at diagnosis are at risk for TLS when treatment starts, which can cause kidney damage and dangerous electrolyte abnormalities. Aggressive hydration, allopurinol, and sometimes rasburicase are given preventively.
• Leukapheresis: If the white blood cell count is extremely high (>100,000/µL) with symptoms, leukapheresis (mechanical removal of white cells from the blood) may be used as a temporary emergency measure before chemotherapy takes effect.
• Psychosocial support: AML diagnosis and prolonged hospitalization are psychologically overwhelming. Social work, psychology services, chaplaincy, and peer support are essential components of care.

• Am I a candidate for intensive or lower-intensity treatment, and why?
• Do I have any mutations that have a specific targeted therapy?
• If I have FLT3, will midostaurin or quizartinib be added to my induction from day 1?
• What is the plan if I do not achieve remission after the first cycle?
• What consolidation therapy will I receive after remission?
• Should I be starting a donor search for transplant now?
• What MRD testing will you perform, and how will results guide next steps?
• What infections should I be most worried about, and what prophylaxis am I on?
• Is there a clinical trial I should consider for my specific situation?
• Am I eligible for maintenance therapy after completing consolidation?

A stem cell transplant is the most powerful tool against AML, but it is also the most demanding, and deciding whether to have one is rarely simple. The core of the decision is a trade-off. On one side is the risk that the leukemia comes back: for intermediate- and especially adverse-risk AML, chemotherapy alone is often not enough to prevent relapse, and transplant offers the best chance of long-term cure. On the other side is the risk of the transplant itself, which includes serious complications such as graft-versus-host disease and, in a meaningful minority of patients, death from the procedure rather than from the disease.

Your team weighs several things to find where you fall on that balance. Your risk category and MRD status estimate how likely the leukemia is to return without a transplant — the higher that risk, the more the transplant is worth its dangers. Your age, fitness, other medical conditions, and the availability of a suitable donor estimate how well you are likely to tolerate the procedure. For favorable-risk AML, the relapse risk is usually low enough that the dangers of transplant are not justified in first remission. For adverse-risk AML, the relapse risk is high enough that transplant is generally recommended for everyone fit enough to have it.

Two things are worth knowing as you have these conversations. First, finding a donor is rarely the obstacle it once was: with modern “half-matched” (haploidentical) transplant techniques, nearly everyone has a potential family donor, so you should not assume transplant is off the table simply because you lack a perfectly matched sibling. Second, this is a decision you make with your team, and it is reasonable — often advisable — to seek a second opinion from a dedicated transplant center, even if you receive most of your care closer to home.

It helps to go into a transplant with a realistic picture of recovery, because it is a longer process than many people expect. The initial hospital stay is usually three to six weeks, but the more important timeline is the months that follow. Your new immune system — rebuilt from the donor's stem cells — takes six to twelve months, sometimes longer, to mature. During that time you remain more vulnerable to infection, you will need to repeat many of your childhood vaccinations once your team advises, and you will have frequent clinic visits, especially during the first hundred days when the risk of complications is highest.

Graft-versus-host disease, in which the donor immune cells react against your body, is the complication that most shapes life after transplant. It can affect the skin, gut, liver, eyes, mouth, and other organs, and it ranges from mild and manageable to serious. Many people need immune-suppressing medication for months to control it, and managing that balance — enough immune activity to keep the leukemia away, not so much that it harms healthy tissue — is a central part of post-transplant care. There is an unexpected silver lining here: mild chronic graft-versus-host disease is associated with a lower chance of the leukemia returning, because the same donor cells that cause it also attack any remaining leukemia.

Recovery is also physical and emotional. Fatigue can persist for many months, and it is common to need a gradual return to work and normal activity. Many transplant centers offer survivorship programs, physical therapy, and psychological support, and using them is a sign of doing recovery well, not of struggling. Most people who reach long-term recovery describe a slow but real return to a full life.

• Intermediate-risk AML in first remission (CR1): Transplant is generally recommended, especially if MRD remains positive.
• Adverse-risk AML in CR1: Transplant is strongly recommended for all fit patients as soon as remission is achieved.
• Favorable-risk AML: Transplant is generally NOT recommended in CR1. It is reserved for relapse or MRD persistence.
• Relapsed AML in second remission (CR2): Transplant is recommended for nearly all patients who achieve a second remission.

Important: Donor searches should begin at diagnosis for intermediate and adverse-risk patients, not after remission is achieved. Finding and preparing a donor takes weeks to months.

Ask: "Has my donor search already started, and do I have a matched or haploidentical option identified?"

Conditioning regimen: Before transplant, you receive high-dose chemotherapy (and sometimes radiation) to destroy remaining leukemia cells and suppress your immune system enough to accept donor cells. There are two main approaches:

• Myeloablative conditioning (MAC): More intensive. Generally used for younger, fitter patients. Higher anti-leukemia effect but more toxicity.
• Reduced-intensity conditioning (RIC): Less intensive. Allows older patients (up to age 70–75 at some centers) to undergo transplant with less toxicity, relying more on the graft-versus-leukemia effect.

Donor types:

• Matched sibling donor (MSD): A brother or sister who is a full HLA match. Historically preferred, but outcomes are now comparable with other donor sources.
• Matched unrelated donor (MUD): Found through registries (Be The Match / NMDP). A full 10/10 HLA match.
• Haploidentical (half-matched) donor: A parent, child, or half-matched sibling. With modern post-transplant cyclophosphamide (PTCy), outcomes are now comparable to matched donors. This has greatly expanded donor availability — nearly all patients have a potential haplo donor.
• Cord blood: Used at some centers, particularly for patients without other donor options.

Recovery timeline: Hospitalization typically lasts 3–6 weeks. Full immune recovery takes 6–12 months or longer. Close outpatient follow-up is required for at least the first 100 days and usually much longer.

GVHD occurs when the donor immune cells recognize the recipient’s body as foreign and attack it. It is the major complication of allogeneic transplant.

• Acute GVHD: Occurs in the first 100 days. Affects skin (rash), gut (diarrhea, nausea), and liver. Ranges from mild to life-threatening.
• Chronic GVHD: Occurs after day 100. Can affect skin, mouth, eyes, lungs, joints, and other organs. Can be mild or disabling. May require immunosuppressive treatment for months to years.

The paradox of GVHD: Mild chronic GVHD is actually associated with lower leukemia relapse rates, because the donor immune system attacking the body also attacks any remaining leukemia cells (graft-versus-leukemia effect). Severe GVHD, however, causes significant morbidity and mortality. The goal is to manage immunosuppression to balance GVHD prevention with preserving the anti-leukemia effect.

Learning that AML has come back, or did not respond to the first treatment, is frightening — but it is not the same as being out of options, and it helps to understand how your team approaches it. The first step is almost always to repeat the molecular testing on a new bone marrow sample. This is not a formality: leukemia evolves over time, and the genetic features that drive it at relapse can be different from those at diagnosis. A new, targetable mutation may have appeared, or a previously minor one may now be dominant. The treatment for relapse is built around the leukemia as it is now, which is why that repeat testing is so important.

The second idea is that, for most people who are otherwise fit, the goal of treatment at relapse is to achieve a second remission and then use it as a bridge to a stem cell transplant, because transplant offers the most realistic chance of long-term control once the disease has returned. This shapes which treatments are chosen: the aim is a remission deep and durable enough to carry you safely to transplant. If you have a targetable mutation, a targeted drug (such as gilteritinib, ivosidenib, enasidenib, or a menin inhibitor) may achieve that remission with fewer side effects than intensive chemotherapy; if not, stronger chemotherapy combinations are used.

The third idea is that relapse is one of the situations where clinical trials are most worth exploring, sometimes as a first choice rather than a last resort. Many of the most promising new approaches in AML — including immune therapies — are studied first in relapsed disease. Asking your team early about trials open for your specific mutations keeps the widest range of options on the table.

Salvage regimens are more intensive chemotherapy combinations used to achieve a second remission, often as a bridge to transplant. Common regimens include:

• FLAG-IDA: Fludarabine + high-dose cytarabine + G-CSF + idarubicin
• CLAG-M: Cladribine + high-dose cytarabine + G-CSF + mitoxantrone
• MEC: Mitoxantrone + etoposide + cytarabine

Second remission rates are lower than first remission rates, and the goal is typically to bridge to allogeneic transplant if the patient has not already received one.

Ask: "Have you repeated the molecular testing on a fresh marrow sample so my relapse treatment matches the leukemia as it is now?"

Molecular testing should be repeated at relapse because mutations can change. New targetable mutations may emerge, or previously present mutations may become more dominant. Key options include:

• Gilteritinib: For FLT3-mutated relapsed/refractory AML
• Ivosidenib or olutasidenib: For IDH1-mutated relapsed/refractory AML
• Enasidenib: For IDH2-mutated relapsed/refractory AML
• Revumenib: For KMT2A-rearranged or NPM1-mutated relapsed/refractory AML

INVESTIGATIONAL The following are in clinical trials and not yet FDA-approved for AML:

• CAR-T cells targeting CD33 or CD123: Unlike in lymphoma, CAR-T for AML is still experimental because AML shares surface markers with normal blood-forming stem cells. Multiple trials are ongoing.
• Bispecific antibodies (flotetuzumab, CD123×CD3): Recruit the patient’s own T cells to attack leukemia. Early trials show activity in relapsed/refractory disease.
• Ziftomenib (Komzifti, menin inhibitor): FDA-APPROVED A second menin inhibitor, FDA-approved November 13, 2025 for R/R AML with NPM1 mutations based on KOMET-001 (NCT04067336). Together with revumenib, there are now two approved menin inhibitors for AML.

Clinical trials carry an unfortunate reputation as something you turn to only when nothing else is left. In AML, that reputation is misleading. Many trials enroll newly diagnosed patients, and a number of today's standard treatments — including venetoclax-based combinations and the FLT3 and menin inhibitors — were available only through trials just a few years ago. Considering a trial is not a sign that your situation is hopeless; it is often a way to access tomorrow's standard of care today, under especially close monitoring.

When weighing a specific trial, it helps to ask a focused set of questions: What is being tested, and how does it compare with the standard treatment I would otherwise receive? Is there a chance I would receive a placebo, and if so, would I still get standard treatment alongside it? What extra visits, tests, or travel are involved, and who covers those costs? What are the known risks of the experimental treatment, and how will the team monitor for them? A good trial team will answer these openly, and asking them does not obligate you to enroll.

You do not have to find trials alone. The Leukemia & Lymphoma Society runs a free Clinical Trial Support Center staffed by nurses who help match you to trials based on your exact diagnosis, mutations, and location. Academic leukemia centers often have trials open that are not widely advertised, which is another reason a second opinion at such a center can be valuable. And because eligibility for many trials depends on your specific mutations and how much prior treatment you have had, it is worth asking about trials early — some options are only open before certain treatments are given.

• ClinicalTrials.gov (clinicaltrials.gov): The authoritative US registry. Search for “acute myeloid leukemia” and filter by status (recruiting), location, and mutation type.
• Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center: 1-800-955-4572. Free nurse navigators who help match you to trials based on your specific disease and location.
• ASH (American Society of Hematology): Annual meeting abstracts often report the newest AML trial results.
• Your academic leukemia center: Many centers run trials not widely advertised. Ask your hematologist what trials they have open for your mutation profile.
• Be The Match / NMDP: Resources for transplant-related clinical trials.

Do not assume trials are a “last resort.” Many AML trials are for newly diagnosed patients. Some of today’s standard treatments (midostaurin, venetoclax + azacitidine) were yesterday’s clinical trials.

Ask: "Is there a clinical trial open for my exact mutations, and am I still eligible before my next treatment starts?"

Because AML drugs are approved on different timelines in different countries, you may read about a treatment — a newly approved menin inhibitor, for example — that is not yet available in your region. This is a common and frustrating situation, but there are constructive steps to take. The first is to confirm with your hematologist whether the drug is genuinely unavailable or simply not yet routinely funded; sometimes a treatment is approved but access is restricted by cost or by the local health system's review process, which can have appeal or exception pathways.

Where a drug is truly not yet approved locally, ask specifically about three routes. The first is a clinical trial of the same or a similar drug, which may be open in your country or a neighboring one. The second is a compassionate-use or expanded-access program, through which manufacturers sometimes provide an unapproved drug to patients who have no other good options; your specialist center can tell you whether such a program exists and how to apply. The third, where feasible, is referral to or consultation with a center in a region where the drug is approved.

It also helps to know that the underlying standards of AML care — the way risk is classified, the molecular testing that should be done, and the major treatment principles — are remarkably consistent worldwide, guided by international frameworks such as the European LeukemiaNet classification. So while a specific newer drug may not be available everywhere, the core of high-quality care is, and a difference in one drug's availability rarely means a difference in the overall standard of treatment you can expect.

• ELN (European LeukemiaNet): Publishes the internationally used risk classification system (ELN 2022)
• NCCN (US): Comprehensive treatment algorithms
• ESMO (Europe): Clinical practice guidelines
• NICE (UK): Technology appraisals determining NHS access
• HOVON/SAKK (Netherlands/Switzerland): Major AML cooperative trial group
• ALFA (France): Influential AML trial group
• SAL (Germany): Study Alliance Leukemia
• UK NCRI: AML17/19 trials established optimal anthracycline dosing
• JALSG (Japan): Japan Adult Leukemia Study Group
• Health Canada / CADTH: Canadian drug access pathway

When you or your family search for information about AML, you will inevitably encounter stories about exciting new treatments — some legitimate, some exaggerated, and some misleading. The history of AML offers a valuable lesson for reading these stories critically. Several treatments described in this section, such as magrolimab, generated genuine excitement on the basis of early results, only to fail when tested rigorously in large randomized trials. This is not unusual: many treatments that look promising in small, early studies do not hold up when compared head-to-head against standard care in larger ones.

The single most useful question to ask about any treatment you read about is: what kind of evidence supports it? Early-phase results (often described as “phase 1” or “phase 2,” or as a small study without a comparison group) can be encouraging but are not proof of benefit. The strongest evidence comes from randomized phase 3 trials, in which the new treatment is directly compared against the current standard in a large number of patients. A treatment that has improved survival in such a trial stands on much firmer ground than one supported only by anecdotes or early data.

This is also a useful filter for evaluating treatments offered outside mainstream medicine, including expensive “alternative” or unproven therapies. A simple, fair question to bring to your hematologist about anything you are considering is: “Has this been tested in a randomized trial for AML, and what did it show?” If the honest answer is that it has not, that does not automatically make it worthless — but it does mean the claims about it should be treated with caution, and that a clinical trial is usually the safest way to access a genuinely promising experimental option.

WITHDRAWN/REFORMULATED The original 2000 FDA approval used a higher dose (9 mg/m²) that caused excess hepatic veno-occlusive disease (VOD) and treatment-related mortality without clear survival benefit in the confirmatory SWOG S0106 trial. The drug was voluntarily withdrawn from the US market in 2010. It was later re-approved in 2017 at a lower, fractionated dose (3 mg/m² on days 1, 4, 7) based on the ALFA-0701 trial, which showed benefit in favorable-risk AML with an acceptable safety profile.

FAILED An antibody-drug conjugate targeting CD33 that was in development by Seattle Genetics (now Seagen). The phase 3 CASCADE trial (NCT02785900) in older, newly diagnosed AML was terminated in 2017 due to a higher rate of deaths, including fatal infections, in the treatment arm compared to placebo + HMA. Development was discontinued.

DE-ADOPTED Glasdegib, a hedgehog pathway inhibitor combined with low-dose cytarabine, received FDA approval in 2018 for newly diagnosed AML in patients ineligible for intensive chemotherapy. However, its adoption was limited because venetoclax-based combinations demonstrated substantially superior efficacy in the same patient population. Glasdegib + LDAC achieved lower response rates and shorter survival compared to venetoclax + azacitidine. It is rarely used in current practice.

FAILED Magrolimab, an anti-CD47 antibody developed by Gilead, generated significant excitement based on promising phase 1b/2 data in combination with azacitidine for AML and MDS. However, all hematology studies were terminated: ENHANCE (higher-risk MDS) was terminated for futility in July 2023, ENHANCE-2 (AML) was terminated in September 2023, and ENHANCE-3 was terminated in February 2024. The FDA placed a full clinical hold on the program. Gilead discontinued all hematology-oncology development of magrolimab. This is a cautionary example that promising early-phase results do not always translate to confirmed benefit in phase 3 trials.

• Based on my risk category and MRD status, do I need a transplant?
• What donor options do I have (sibling, unrelated, haploidentical)?
• What conditioning regimen do you recommend (MAC vs. RIC)?
• What are the expected rates of GVHD, relapse, and transplant-related mortality?
• If I relapse, should molecular testing be repeated?
• Is there a clinical trial open for my situation?
• What is the role of maintenance therapy after transplant?
• Are CAR-T trials available for AML at your center?

The figures below are approximate US list prices (wholesale acquisition cost) as of 2026, rounded for orientation. They are not what most patients pay: insurance, the Medicare Part D cap, copay cards, and assistance programs usually reduce out-of-pocket cost to a small fraction of these numbers. List prices change frequently — confirm current figures with your specialty pharmacy and your center’s financial navigator.

Ask: "Which of my drugs go through my pharmacy plan versus my medical insurance, and what will each actually cost me after my coverage?" Then ask: "Is there a lower-cost generic or biosimilar for any of my medicines?"

For context, the hospital and facility side is far larger than the drugs: an initial induction hospitalization commonly runs on the order of $100,000, and an allogeneic stem cell transplant frequently exceeds $400,000 in total billed charges (approximate US figures, 2026). These are billed to your medical benefit, where your annual out-of-pocket maximum — not the Part D drug cap — is what limits your exposure.

Most oral AML drugs — venetoclax (Venclexta), gilteritinib (Xospata), ivosidenib (Tibsovo), enasidenib (Idhifa), oral azacitidine (Onureg), and the menin inhibitors revumenib (Revuforj) and ziftomenib (Komzifti) — are covered under Medicare Part D, the prescription-drug benefit. Under the 2025–2026 Part D redesign:

• Your out-of-pocket spending on covered Part D drugs is capped at $2,100 for all of 2026. Once you reach that amount, you pay $0 for covered drugs for the rest of the calendar year (Medicare Part D, 2026).
• No Part D plan may charge a deductible above $615 in 2026 (Medicare Part D, 2026).
• The Medicare Prescription Payment Plan lets you spread that $2,100 across the year in smaller monthly installments instead of paying it all at once — helpful when a costly drug lands early in the year. Ask your drug plan to enroll you.

• Manufacturer copay programs can cut your out-of-pocket cost for a brand-name drug to as little as $0 if you have commercial insurance. (These programs are not available to people with Medicare, Medicaid, or other government coverage.) For venetoclax, the Genentech/AbbVie Access Solutions copay program can be reached at 855-692-6729; every AML drug maker runs a similar program.
• Ask your specialty pharmacy or your center’s financial navigator to enroll you — they do this every day.

• Allopurinol (taken by mouth to help prevent tumor lysis syndrome) is an inexpensive generic — roughly $9 to $15 for a month’s supply as a cash price with a free discount coupon (GoodRx estimate, July 2026).
• Injectable azacitidine and the 7+3 chemotherapy drugs (cytarabine, daunorubicin) are given in the hospital or infusion clinic and billed to your medical benefit, not your pharmacy plan — so a Part D cap does not apply to them; your medical-plan deductible and coinsurance do.

• Leukemia & Lymphoma Society (LLS) Co-Pay Assistance Program: 1-877-557-2672 — grants toward drug copays, insurance premiums, and related costs for blood-cancer patients who qualify.
• Patient Advocate Foundation Co-Pay Relief: copays.org — copay grants for eligible patients.
• Your hospital’s financial navigator or oncology social worker: can screen you for charity care, drug-manufacturer patient-assistance programs (free drug for uninsured or underinsured patients), and travel and lodging grants.

Ask: “Can your financial navigator enroll me in a copay assistance program and the LLS Co-Pay Assistance Program today, and which of my drugs go through my pharmacy plan versus my medical insurance?”

• Expect a long hospital stay. Intensive induction typically requires 4–6 weeks of continuous hospitalization. Plan for this practically: work leave, childcare, bill management, meal logistics.
• Be present but take shifts. Having a caregiver present during rounds (usually 8–10 AM) helps you ask questions and record information. But 24/7 bedside presence is not sustainable. Organize a rotation with family or friends.
• Keep a written log. Track daily lab values (white count, hemoglobin, platelets), temperatures, medications, and questions. This helps you notice trends and communicate with the team.
• Understand the timeline. After chemotherapy ends (day 7), there is a waiting period while blood counts drop to their lowest point (nadir, around days 14–21), then slowly recover. This waiting is normal and expected, but it can feel terrifying.

• Wash hands frequently and thoroughly — this is the single most important infection prevention measure.
• Avoid crowds, sick contacts, and anyone recently vaccinated with live vaccines during neutropenic periods.
• Cook all meat thoroughly. Avoid raw sushi, unpasteurized dairy, unwashed produce, and buffet-style food.
• Keep the home clean but not sterile — normal cleaning is sufficient. No need for hazmat-level precautions.
• Know the fever rule: Any temperature of 100.4°F (38.0°C) or higher during a low white blood cell period is a medical emergency. Go to the emergency department immediately. Do not wait to see if it resolves. Ask: "At what exact temperature should we go to the ER, and who do we call on the way?"

AML patients often need frequent transfusions — sometimes multiple times per week during treatment. Each transfusion visit takes 2–4 hours. Tips:

• Know the outpatient infusion center hours and whether appointments or walk-ins are available.
• Keep a list of blood type and any alloantibodies (some patients develop antibodies that make finding compatible blood harder).
• Bring entertainment, snacks, and comfort items for transfusion visits.
• Ask about home transfusion services if available in your area.

• Talk about what matters. AML forces difficult conversations early. Goals of care, advance directives, and healthcare power of attorney should be discussed when the patient is well enough to participate, not during a crisis.
• Seek professional support. Social workers, psychologists, and chaplains at cancer centers are experienced with leukemia-specific challenges. Use them.
• Caregiver burnout is real. You cannot care for someone else if you are depleted. Eat properly, sleep, accept help, and take breaks. This is not selfish — it is necessary.
• Connect with other AML families. The Leukemia & Lymphoma Society (LLS) at 1-800-955-4572 offers peer-to-peer support, and online communities (HealthUnlocked AML group, Smart Patients) connect caregivers going through similar experiences.

• “acute myeloid leukemia venetoclax azacitidine VIALE-A”
• “midostaurin 7+3 FLT3 RATIFY”
• “gilteritinib relapsed FLT3 ADMIRAL”
• “quizartinib FLT3-ITD QuANTUM-First”
• “ivosidenib azacitidine IDH1 AGILE”
• “revumenib menin inhibitor KMT2A NPM1 AUGMENT-101”
• “oral azacitidine maintenance AML QUAZAR”
• “CPX-351 Vyxeos secondary AML”
• “sorafenib maintenance post-transplant FLT3 SORMAIN”

• “ziftomenib NPM1 AML KOMET-007”
• “CAR-T CD33 acute myeloid leukemia”
• “CAR-T CD123 AML”
• “flotetuzumab bispecific CD123 AML”
• “magrolimab CD47 AML”
• “TP53 mutated AML clinical trial”
• “MRD-guided therapy AML”